Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Surgical "Window-of-Opportunity" and Phase II Trial of Pembrolizumab, Olaparib and Temozolomide in Recurrent Glioblastoma

NCT05463848 is registered in ClinicalTrials.gov with L. Nicolas Gonzalez Castro, MD, PhD as lead sponsor.

NCT NCT05463848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05463848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Surgical "Window-of-Opportunity" and Phase II Trial of Pembrolizumab, Olaparib and Temozolomide in Recurrent Glioblastoma
Lead sponsor
L. Nicolas Gonzalez Castro, MD, PhD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 21, 2022
Completion date
March 1, 2027
Enrollment
52 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, recurrent glioblastoma